DDInter915 DDInter448
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Indacaterol {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Indacaterol {u} (Compound) resembles {v} (Compound) Procaterol
Procaterol {u} (Compound) upregulates {v} (Gene) ICAM1
ICAM1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Indacaterol {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Indacaterol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Indacaterol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Indacaterol (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Indacaterol (Compound) resembles Procaterol (Compound) and Procaterol (Compound) upregulates ICAM1 (Gene) and ICAM1 (Gene) is upregulated by Crizotinib (Compound)
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Crizotinib (Compound)
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Indacaterol (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib